01 Tomosynthesis-Guided Vacuum Biopsy Improves Lesion Targeting Breast biopsy market analysis shows that wider use of digital breast tomosynthesis is shifting biopsy procedures toward tomosynthesis-guided vacuum sampling for lesions that are difficult to identify with conventional imaging. A September 2025 meta-analysis of 1,361 tomosynthesis-only architectural distortion lesions found a 37% pooled malignancy rate, supporting tissue sampling of these findings. This transition improves access to targeted biopsy for subtle architectural distortions that may not have a clear ultrasound correlate.
02 MRI-Guided Vacuum Biopsy Expands Diagnosis of MRI-Only Lesions Identification of suspicious lesions visible only on breast MRI is shifting biopsy systems toward MRI-guided vacuum-assisted procedures that can obtain tissue from otherwise difficult-to-target sites. A 2026 study of 292 MRI-only lesions reported a 28.4% malignancy rate, while histopathological discordance occurred in 6.5% of cases. This transition expands tissue diagnosis for MRI-detected abnormalities while reinforcing the role of radiologic-pathologic concordance after biopsy.
01 Breast Cancer Screening and Ultrasound-Guided Biopsy Expansion Drive Market Breast cancer screening identifies suspicious abnormalities that may require tissue sampling for definitive diagnosis, creating a direct increase in demand for biopsy procedures. The NCI notes that suspicious or highly suspicious mammography findings may require biopsy as part of the diagnostic pathway. This screening-to-biopsy pathway supports continued use of core needle, vacuum-assisted, and other biopsy methods. Wider screening activity therefore expands the patient base requiring breast biopsy services.Ultrasound-guided procedures provide real-time visualization of breast abnormalities and allow radiologists to guide needles directly into suspicious masses. Current RadiologyInfo guidance identifies core needle and vacuum-assisted devices as established applications for ultrasound-guided breast biopsy. The use of these procedures across palpable masses, solid lesions, and abnormal tissue changes expands applications for biopsy needles and associated equipment. This broader clinical use strengthens demand for ultrasound-compatible biopsy devices.
01 Breast Radiologist Shortages and Limited Imaging Infrastructure Restrain Market Expansion Limited availability of trained breast radiologists can reduce the capacity of healthcare facilities to perform image-guided biopsy procedures, especially where diagnostic workloads are high. Accurate lesion assessment and biopsy guidance require specialized clinical expertise, making staffing gaps a direct constraint on procedure availability. This shortage can extend waiting times and slow the adoption of advanced breast biopsy technologies.Uneven availability of mammography, ultrasound, MRI, and biopsy-support equipment can restrict access to image-guided diagnostic procedures across healthcare facilities. Rural and lower-resource settings may lack the infrastructure needed to identify and accurately target suspicious breast lesions. Such infrastructure gaps can reduce procedure volumes and constrain breast biopsy market penetration across underserved regions.
01 AI-Assisted Pathology and Digital Specimen Management Offer Growth Opportunities Pathology technology providers and biopsy equipment companies can integrate AI-assisted tissue analysis with biopsy workflows to support biomarker assessment and diagnostic review. PathAI, for example, expanded its digital pathology ecosystem in 2025 through partnerships covering breast cancer biomarkers and prognostic analysis. Such integrations can create revenue through software subscriptions, diagnostic modules, and workflow solutions, contributing to breast biopsy market growth.Hospitals, pathology laboratories, and diagnostic technology providers can develop digital systems for biopsy specimen tracking, slide management, remote review, and laboratory workflow coordination. A 2025 study involving Tata Memorial Hospital demonstrated that digital pathology reduced turnaround time and costs in breast cancer HER2 testing by enabling remote slide sharing. These solutions can generate recurring revenue through software licensing, workflow platforms, and laboratory integration services.
01 Biopsy Device Supply Disruptions and Radiologic-Pathologic Discordance Hinder Growth Supply interruptions for specialized biopsy needles can create procurement uncertainty for hospitals and device suppliers, affecting scheduled procedures and inventory planning. In June 2026, the FDA reported an ongoing U.S. shortage of stereotactic breast biopsy needles, with the disruption expected to extend through March 2027. Such shortages can delay procedures, increase inventory-management costs, and make market expansion more difficult for device manufacturers and healthcare providers.Differences between imaging findings and biopsy results can require additional sampling or surgical assessment, adding complexity to the diagnostic pathway. A 2025 consensus document recommends repeat biopsy when benign histology does not adequately explain suspicious imaging findings, while a 2026 systematic review reported clinically meaningful malignancy-upgrade risks in discordant cases. These additional procedures can increase healthcare costs and make providers more cautious about adopting new biopsy technologies.
April 2026 Hologic completed its acquisition by Blackstone and TPG, transitioning into a privately held company while maintaining its focus on women’s health technologies, including breast health and biopsy solutions. The transaction supported future investments in innovation and expansion of Hologic’s diagnostic and interventional breast health portfolio.
February 2026 Mammotome, a Danaher business, introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy System, designed specifically for use inside the MRI scanner room during breast biopsy procedures. The system positioned the vacuum-assisted biopsy device closer to the patient during MRI-guided procedures, improving workflow coordination and supporting more efficient lesion sampling.
January 2026 BD (Becton, Dickinson and Company) received U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System. The multi-modality breast biopsy platform was developed to support procedures across different breast imaging modalities, providing clinicians with improved procedural flexibility for breast disease diagnosis.
January 2026 Devicor Medical Products received U.S. FDA 510(k) clearance for the HydroMARK™ Plus Breast Biopsy Site Marker in Dragonfly and Hummingbird shapes. The approval expanded Devicor’s breast biopsy marker portfolio by introducing additional marker designs intended for radiographic identification and post-biopsy lesion localization.